ApneaLink Air Home Sleep Testing (HST) Device Validation Study

The current gold standard for sleep disordered breathing (SDB) diagnosis is in-laboratory
polysomnography (PSG). A barrier of acceptance of Home Sleep Apnea Testing (HSAT) devices as
a diagnostic test is their inability to accurately measure total sleep time (TST). A novel
algorithm developed by ResMed, Ltd. allows the AL device to accurately calculate TST,
however, this algorithm has not yet been validated.

The ApneaLink Air (AL) device is a type III HSAT device. The device is capable of recording
up to four channels of data including: flow and snore via a nasal cannula attached to a
pressure transducer, a respiratory effort belt, a pulse oximeter to measure pulse and oxygen
saturation, and an actigraphy monitor to measure TST along with flow. The AL device has been
validated against PSG for AHI, and Cheyne-Stoke respiration detection . Further validation of
the effort belt is necessary to determine the accuracy of the AL ability to differentiate
between obstructive and central apneic events.

Inclusion Criteria:

- Participant is 18 years of age or older

- Participant is willing to provide informed consent

- Participant is willing to participate in all study related procedures

Exclusion Criteria:

- Unable to cease positive airway pressure (PAP) therapy during PSG (if currently using)

- Requires use of oxygen therapy during sleep

- Diagnosis of uncontrolled clinically relevant sleep disorder (e.g., untreated insomnia
or restless leg syndrome)

- Pregnant

- Participant is unsuitable to participate in the study in the opinion of the
investigator